Comparison of the PapilloCheck® DNA micro-array Human Papillomavirus detection assay with Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer set

Journal of Clinical Virology

Volumn 45, Issue 2, 2009, Pages 100-104

  Jones, J ^a   Powell, N G ^a   Tristram, A ^a   Fiander, A N ^a   Hibbitts, S ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cervical screening; Cytology; HPV testing; Hybrid Capture II; PapilloCheck

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DNA MICROARRAY; ENZYME IMMUNOASSAY; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYBRID CAPTURE 2; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS; COMPARATIVE STUDY; DIAGNOSTIC PROCEDURE; EVALUATION; GENETICS; ISOLATION AND PURIFICATION; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PAPILLOMA VIRUS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX; VIROLOGY;

ADULT; AGED; CERVIX UTERI; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 67349083893     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.02.013     Document Type: Article

References (31)

1. Office for National Statistics. England and Wales: Mortality Statistics; 2006.
2. Scottish Health Statistics 2006 ISD Scotland.
3. Welsh Cancer Intelligence and Surveillance Unit. Cancer Mortality in Wales; 2006.
4. Northern Ireland Cancer Registry. Cancer Mortality in Northern Ireland; 2006.
5. Hibbitts S., Jones J., Powell N., Dallimore N., McRea J., Beer H., Tristram A., Fielder H., and Fiander A.N. Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study. Br J Cancer 99 11 (2008) 1929-1933
6. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 5 (2006) 1095-1101
7. Cuzick J., Szarewski A., Cubie H., Hulman G., Kitchener H., Luesley D., et al. Management of women who test positive for high-risk types of Human Papillomavirus: the HART study. Lancet 362 9399 (2003) 1871-1876
8. Sherman M.E., Lorincz A.T., Scott D.R., Wacholder S., Castle P.E., Glass A.G., et al. Baseline cytology, Human Papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95 1 (2003) 46-52
9. Davies P., Arbyn M., Dillner J., Kitchener H.C., Meijer C.J., Ronco G., et al. A report on the current status of European research on the use of Human Papillomavirus testing for primary cervical cancer screening. Int J Cancer 118 4 (2006) 791-796
10. Mayrand M.H., Duarte-Franco E., Coutlée F., Rodrigues I., Walter S.D., Ratnam S., et al. Randomized controlled trial of Human Papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 119 3 (2006) 615-623
11. Schwartz S.M., Daline J.R., Shera K.A., Madeleine M.M., McKnight B., and Galloway D.A. Human Papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol 19 (2001) 1906-1915
12. Lai C.H., Chang C.J., Huang H.J., Hsueh S., Chao A., and Yang J.E. Role of Human Papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery. J Clin Oncol 25 (2007) 3628-3634
13. Pilch H., Gunzel S., Schaffer U., Tanner B., Brockerhoff P., and Maeurer M. Human Papillomavirus (HPV) DNA in primary cervical cancer and in cancer free pelvic lymph nodes-correlation with clinico-pathological parameters and prognostic significance. Zentralbl Gynakol 123 (2001) 91-101
14. Arbyn M., Paraskevaidis E., Martin-Hirsch P., Prendiville W., and Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 99 3 (Suppl. 1) (2005) S7-S11
15. Shalini L., Kulasingham S.L., Kim J.J., Lawrence W.F., Mandelblatt J.S., Myers E.R., et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage Study (ALTS). J Natl Cancer Inst 98 2 (2006) 92-100
16. Moss S., Gray A., Legood R., Vessey M., Patnick J., and Kitchener H. Effect of testing for Human Papillomavirus as a triage during screening for cervical cancer: observational before and after study. Br Med J 332 7533 (2006) 83-85
17. Solomon D., Schiffman M., and Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trail. J Natl Cancer Inst 93 4 (2001) 293-299
18. Sargent A., Bailey A., Almonte M., Turner A., Thomson C., Peto J., et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 98 (2008) 1704-1709
19. Cotton S.C., Sharp L., Little J., Duncan I., Alexander L., Cruickshank M.E., et al. Trial of management of borderline and other low-grade abnormal smears (TOMBOLA): trial design. Contemp Clin Trials 5 (2006) 449-471
20. Coupe V.M., Berkhof J., Bulkmans N.W., Snijders P.J., and Meijer C.J. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 98 3 (2008) 646-651
21. Advice for Cytopathology Laboratories on the Implementation of Liquid Based Cytology for Cervical Screening LBC. Implementation Guide 2004; no. 2 [Version 1].
22. ® Test kit for the genotyping of 24 types of genital HPV. Instruction Manual 2007; May [Version BQ-013-02].
23. Digene Corporation. hc2 High-Risk HPV DNA Test. Test Instruction Booklet; 2006.
24. Hibbitts S., Rieck G.C., Hart K., Powell N.G., Beukenholdt R., Dallimore N., et al. Human Papillomavirus infection: an anonymous prevalence study in South Wales, UK. Br J Cancer 95 2 (2006) 226-232
25. Jacobs M.V., Snijders P.J., van den Brule A.J., Helmerhorst T.J., Meijer C.J., and Walboomers J.M. A general primer GP5/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk Human Papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35 3 (1997) 791-795
26. Poljak M., Marin I., Seme K., and Vince A. Hybrid Capture II HPV test detects at least 15 Human Papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol 25 Suppl. 3 (2002) S89-S97
27. Baleriola C., Millar D., Melki J., Coulston N., Altman P., Rismanto N., et al. Comparison of a novel HPV test with the Hybrid Capture II (hcII) and a reference PCR method shows high specificity and positive predictive value for 13 high-risk Human Papillomavirus infections. J Clin Virol 42 1 (2008) 22-26
28. Wall S.R., Scherf C.F., Morison L., Hart K.W., West B., Ekpo G., et al. Cervical Human Papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. Br J Cancer 93 9 (2005) 1068-1076
29. Petry K.U., Menton S., Menton M., van Leonen-Frosch F., de Carvalho Gomes H., Holz B., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 88 (2003) 1570-1577
30. Saseini P., and Cuzick J. Can HPV testing become the sole primary cervical screening test?. J Med Screen 9 (2002) 49-51
31. Cuzick J., Sasieni P., Davies P., Adams J., Normand C., Frater A., et al. Estimates of the cost impact of introducing Human Papillomavirus testing into a cervical screening programme. In: Franco E., and Monsonego J. (Eds). New developments in cervical cancer screening and prevention (1997), Blackwell Science, Oxford 364-372